Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
NewsPartner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. INCY
stocks logo

INCY

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
1.25B
+10.22%
1.671
+56.15%
1.32B
+11.58%
1.804
+26.16%
1.18B
+12.38%
1.347
+16.11%
Estimates Revision
The market is revising Upward the revenue expectations for Incyte Corporation (INCY) for FY2025, with the revenue forecasts being adjusted by 0.12% over the past three months. During the same period, the stock price has changed by 30.39%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.12%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.14%
In Past 3 Month
Stock Price
Go Up
up Image
+30.39%
In Past 3 Month
17 Analyst Rating
up Image0
Wall Street analysts forecast INCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INCY is 79.60 USD with a low forecast of 52.00 USD and a high forecast of 107.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
9 Hold
1 Sell
Moderate Buy
up Image0
Current: 77.650
sliders
Low
52.00
Averages
79.60
High
107.00
up Image0
Current: 77.650
sliders
Low
52.00
Averages
79.60
High
107.00
Wells Fargo
Equal Weight
to
Overweight
upgrade
$67 -> $89
2025-08-06
New
Reason
Wells Fargo
Price Target
$67 -> $89
2025-08-06
New
upgrade
Equal Weight
to
Overweight
Reason
Wells Fargo upgraded Incyte to Overweight from Equal Weight with a price target of $89, up from $67. The firm believes the company's Phase 1 update for myelofibrosis in Q4 will be positive. In addition, the potential for research and development "rationalization" along with future business development provides upside for the stock, the analyst tells investors in a research note. Wells believes Incyte can address its Jakafi loss of exclusivity.
Barclays
Overweight
initiated
$90
2025-08-01
Reason
Barclays
Price Target
$90
2025-08-01
initiated
Overweight
Reason
Barclays initiated coverage of Incyte with an Overweight rating and $90 price target. The firm sees \"value-inflecting\" data readouts for the company in the second half of 2025 and 2026. It believes the pivotal data for tafasitamab in diffuse large B-cell lymphoma and the Phase 2 data for povorcitinib in chronic spontaneous urticaria patients as providing the next legs of growth for Incyte.
Citi
Buy
maintain
$88 -> $103
2025-07-30
Reason
Citi
Price Target
$88 -> $103
2025-07-30
maintain
Buy
Reason
Citi raised the firm's price target on Incyte to $103 from $88 and keeps a Buy rating on the shares post the Q2 report. The company reported another beat and guidance raise for Jakafi with upside for Niktimvo, the analyst tells investors in a research note.
UBS
Neutral
maintain
$62 -> $68
2025-07-30
Reason
UBS
Price Target
$62 -> $68
2025-07-30
maintain
Neutral
Reason
UBS raised the firm's price target on Incyte to $68 from $62 and keeps a Neutral rating on the shares.
BMO Capital
Evan Seigerman
Underperform
maintain
$52 -> $60
2025-07-30
Reason
BMO Capital
Evan Seigerman
Price Target
$52 -> $60
2025-07-30
maintain
Underperform
Reason
BMO Capital analyst Evan Seigerman raised the firm's price target on Incyte to $60 from $52 but keeps an Underperform rating on the shares after its Q2 earnings beat. While the firm is encouraged by earnings, there is work to be done, the analyst tells investors in a research note. BMO adds that it "appreciates the perspective of impartiality" when assessing internal and external growth opportunities, but Incyte's modest cash positioning could be growth-limiting for transactions.
Truist
Srikripa Devarakonda
Hold
maintain
$73 -> $79
2025-07-30
Reason
Truist
Srikripa Devarakonda
Price Target
$73 -> $79
2025-07-30
maintain
Hold
Reason
Truist analyst Srikripa Devarakonda raised the firm's price target on Incyte to $79 from $73 and keeps a Hold rating on the shares after its Q2 earnings and revenue beat. Increased demand from Jakafi exceeded expectations, but the looming Jakafi loss of exclusivity remains a key overhang, and the firm remains on the sidelines for now, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Incyte Corp (INCY.O) is 12.01, compared to its 5-year average forward P/E of 20.39. For a more detailed relative valuation and DCF analysis to assess Incyte Corp 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
20.39
Current PE
12.01
Overvalued PE
28.20
Undervalued PE
12.58

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
16.97
Current EV/EBITDA
7.91
Overvalued EV/EBITDA
26.49
Undervalued EV/EBITDA
7.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
4.38
Current PS
3.00
Overvalued PS
5.78
Undervalued PS
2.99

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

INCY News & Events

Events Timeline

(ET)
2025-08-06
08:47:54
Actuate, Incyte, University of Pittsburgh collaborate on elraglusib trial
select
2025-07-29 (ET)
2025-07-29
07:26:13
Incyte raises FY25 Jakafi revenue view to $3B-$3.05B from $2.95B-$3B
select
2025-07-29
07:24:53
Incyte reports Q2 EPS $1.57, consensus $1.48
select
Sign Up For More Events
Sign Up For More Events

News

Preview
7.5
08-04Globenewswire
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America

  • Knight Therapeutics Expands Partnership: Knight Therapeutics Inc. has amended its agreement with Incyte Biosciences to exclusively distribute retifanlimab and axatilimab in Latin America, enhancing its oncology and hematology portfolio.

  • Product Approvals and Market Potential: Retifanlimab is approved for treating Merkel cell carcinoma and squamous cell carcinoma, while axatilimab is approved for chronic graft-versus-host disease, addressing significant medical needs in the region with thousands of new cases reported annually.

Preview
6.0
08-01Benzinga
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Friday

  • Analyst Ratings Updates: Needham analyst Gerald Pascarelli has initiated coverage on Turning Point Brands, Inc. (TPB) with a Hold rating, while Barclays analyst Luke Sergott has given Incyte Corporation (INCY) an Overweight rating with a price target of $90.

  • Stock Performance: As of Thursday, Turning Point Brands shares closed at $82.94 and Incyte shares at $74.89, reflecting the analysts' differing outlooks on these companies.

Preview
9.0
08-01Newsfilter
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Brazil

  • Regulatory Submission: Knight Therapeutics' Brazilian affiliate has submitted a supplemental application to ANVISA for MINJUVI® (tafasitamab) in combination with rituximab and lenalidomide to treat adult patients with previously treated follicular lymphoma, highlighting their commitment to enhancing patient care.

  • Clinical Trial Results: The submission is based on positive results from the Phase 3 inMIND trial, which showed that the combination therapy significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma compared to placebo.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Incyte Corp (INCY) stock price today?

The current price of INCY is 77.65 USD — it has decreased -0.1 % in the last trading day.

arrow icon

What is Incyte Corp (INCY)'s business?

Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.

arrow icon

What is the price predicton of INCY Stock?

Wall Street analysts forecast INCY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INCY is 79.60 USD with a low forecast of 52.00 USD and a high forecast of 107.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Incyte Corp (INCY)'s revenue for the last quarter?

Incyte Corp revenue for the last quarter amounts to 1.22B USD, increased 16.46 % YoY.

arrow icon

What is Incyte Corp (INCY)'s earnings per share (EPS) for the last quarter?

Incyte Corp. EPS for the last quarter amounts to 2.04 USD, decreased -200.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Incyte Corp (INCY)'s fundamentals?

The market is revising Upward the revenue expectations for Incyte Corporation (INCY) for FY2025, with the revenue forecasts being adjusted by 0.12% over the past three months. During the same period, the stock price has changed by 30.39%.
arrow icon

How many employees does Incyte Corp (INCY). have?

Incyte Corp (INCY) has 2617 emplpoyees as of August 07 2025.

arrow icon

What is Incyte Corp (INCY) market cap?

Today INCY has the market capitalization of 15.16B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free